The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection

Trends in Molecular Medicine

Volumn 21, Issue 5, 2015, Pages 319-329

  Thomas, Kimberly A ^a   Valenzuela, Nicole M ^a   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody mediated rejection; Classical complement pathway; HLA antibodies; Organ transplantation

Indexed keywords

COMPLEMENT; FC RECEPTOR; HLA ANTIBODY; IMMUNOGLOBULIN G; ANTIBODY; HLA ANTIGEN;

ALLELE; ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; COMPLEMENT ACTIVATION; DISEASE CLASSIFICATION; ENDOTHELIUM; GRAFT DYSFUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; INFLAMMATION; LONG TERM SURVIVAL; ORGAN TRANSPLANTATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; REVIEW; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM; GRAFT REJECTION; HLA ANTIGENS; HUMANS; RECEPTORS, IGG;

EID: 84929050262     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.02.004     Document Type: Review

References (114)

1. Gupta G., et al. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation 2014, 97:1240-1246.
2. Sellares J., et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am. J. Transplant. 2013, 13:971-983.
3. Sis B., et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am. J. Transplant. 2009, 9:2312-2323.
4. Wu G.W., et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J. Heart Lung Transplant. 2009, 28:417-422.
5. Kfoury A.G., et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 2012, 31:46-51.
6. Loupy A., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am. J. Transplant. 2009, 9:2561-2570.
7. Robinson J., et al. The IMGT/HLA database. Nucleic Acids Res. 2011, 39:D1171-D1176.
8. De Clippel D., et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion 2014, 54:3036-3042.
9. Kakaiya R.M., et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion 2010, 50:1328-1334.
10. Everly M.J., et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013, 95:410-417.
11. Kaneku H., et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am. J. Transplant. 2013, 13:1541-1548.
12. Wiebe C., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 2012, 12:1157-1167.
13. Halloran P.F., et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J. Am. Soc. Nephrol. 2014, Published online November 6, 2014. http://dx.doi.org/10.1681/ASN.2014060588.
14. Frank R., et al. Circulating donor-specific anti-human leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy. Am. J. Clin. Pathol. 2014, 142:809-815.
15. Torres I.B., et al. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection. Clin. Transplant. 2014, 28:1148-1154.
16. Haas M., et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 2014, 14:272-283.
17. Berry G.J., et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 2013, 32:1147-1162.
18. Drachenberg C.B., et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts - updated Banff grading schema. Am. J. Transplant. 2011, 11:1792-1802.
19. Fishbein G.A., Fishbein M.C. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum. Immunol. 2012, 73:1213-1217.
20. Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr. Opin. Organ Transplant. 2013, 18:319-326.
21. O'Leary J.G., et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transplant. 2014, 20:1244-1255.
22. DeNicola M.M., et al. Pathologic findings in lung allografts with anti-HLA antibodies. J. Heart Lung Transplant. 2013, 32:326-332.
23. Farmer D.G., et al. Pretransplant predictors of survival after intestinal transplantation: analysis of a single-center experience of more than 100 transplants. Transplantation 2010, 90:1574-1580.
24. Lefaucheur C., et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013, 381:313-319.
25. Tavora F., et al. Endothelitis in cardiac allograft biopsy specimens: possible relationship to antibody-mediated rejection. J. Heart Lung Transplant. 2011, 30:435-444.
26. Halloran P.F., et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am. J. Transplant. 2013, 13:2865-2874.
27. Vidarsson G., et al. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014, 5:520.
28. Aalberse R.C., Schuurman J. IgG4 breaking the rules. Immunology 2002, 105:9-19.
29. Lucisano Valim Y.M., Lachmann P.J. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin. Exp. Immunol. 1991, 84:1-8.
30. Murata K., Baldwin W.M. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant. Rev. (Orlando) 2009, 23:139-150.
31. Murata K., et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am. J. Transplant. 2007, 7:2605-2614.
32. Rahimi S., et al. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am. J. Transplant. 2004, 4:326-334.
33. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012, 119:5640-5649.
34. Cicciarelli J.C., et al. Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients. Clin. Transpl. 2013, 2013:413-422.
35. Kaneku H., et al. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transplant. 2012, 18:984-992.
36. Kushihata F., et al. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004, 78:995-1001.
37. Schaub S., et al. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014, 98:387-393.
38. Everly M.J., et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 2014, 97:494-501.
39. Honger G., et al. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010, 89:1471-1475.
40. Wasowska B.A., et al. New concepts of complement in allorecognition and graft rejection. Cell. Immunol. 2007, 248:18-30.
41. Hirohashi T., et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am. J. Transplant. 2010, 10:510-517.
42. Hamer R., et al. Human leukocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor C4. Transplantation 2012, 93:867-873.
43. Orandi B.J., et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014, 98:857-863.
44. Stegall M.D., et al. The role of complement in antibody-mediated rejection in kidney transplantation. Nat. Rev. Nephrol. 2012, 8:670-678.
45. Chin C., et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J. Heart Lung Transplant. 2011, 30:158-163.
46. Piazza A., et al. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival. Clin. Transpl. 2013, 2013:367-375.
47. Sutherland S.M., et al. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr. Transplant. 2012, 16:12-17.
48. Lawrence C., et al. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 2013, 95:341-346.
49. Hönger G., et al. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011, 92:41-47.
50. Ehrnthaller C., et al. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol. Med. 2011, 17:317-329.
51. Diebolder C.A., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
52. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8:226-234.
53. Muczynski K.A., et al. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J. Am. Soc. Nephrol. 2003, 14:1336-1348.
54. Mannam V.K., et al. The fate of renal allografts hinges on responses of the microvascular endothelium. Exp. Mol. Pathol. 2013, 94:398-411.
55. AlMahri A., et al. Detection of complement-fixing and non-fixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry. Tissue Antigens 2012, 80:404-415.
56. Jane-Wit D., et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation 2013, 128:2504-2516.
57. Atkinson J.P., et al. H-2 S region determined polymorphic variants of the C4, Slp, C2, and B complement proteins: a compilation. Immunogenetics 1982, 16:617-623.
58. Bay J.T., et al. Low C4 gene copy numbers are associated with superior graft survival in patients transplanted with a deceased donor kidney. Kidney Int. 2013, 84:562-569.
59. Varagunam M., et al. C3 polymorphisms and allograft outcome in renal transplantation. N. Engl. J. Med. 2009, 360:874-880.
60. Terasaki P.I., McClelland J.D. Microdroplet assay of human serum cytotoxins. Nature 1964, 204:998-1000.
61. Dangl J.L., et al. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 1988, 7:1989-1994.
62. Chen G., et al. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum. Immunol. 2011, 72:849-858.
63. Loupy A., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 2013, 369:1215-1226.
64. Sicard A., et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J. Am. Soc. Nephrol. 2014, 26:457-467.
65. Crespo M., et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?. Transpl. Immunol. 2013, 29:28-33.
66. Freitas M.C., et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013, 95:1113-1119.
67. Lachmann N., et al. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013, 95:694-700.
68. Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Curr. Opin. Organ Transplant. 2014, 19:315-322.
69. Xu L., et al. Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens. Clin. Transplant. 2014, 28:554-560.
70. Papadimitriou J.C., et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation 2013, 95:128-136.
71. Hidalgo L.G., et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am. J. Transplant. 2012, 12:1180-1191.
72. Hidalgo L.G., et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am. J. Transplant. 2010, 10:1812-1822.
73. Hirohashi T., et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am. J. Transplant. 2012, 12:313-321.
74. Herter S., et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J. Immunol. 2014, 192:2252-2260.
75. Shashidharamurthy R., et al. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J. Immunol. 2009, 183:8216-8224.
76. Mellor J.D., et al. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 2013, 6:1.
77. Yuan F.F., et al. Association of Fc gamma receptor IIA polymorphisms with acute renal-allograft rejection. Transplantation 2004, 78:766-769.
78. Smith P., et al. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6181-6186.
79. Shin B.H., et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplantation 2014, 97:294-300.
80. Christen T., et al. Molecular imaging of innate immune cell function in transplant rejection. Circulation 2009, 119:1925-1932.
81. Florey O.J., et al. Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between FcγRIIa and CXCR1/2. Blood 2007, 109:3881-3889.
82. Valenzuela N.M., et al. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs. J. Immunol. 2013, 190:6635-6650.
83. Valenzuela N.M., et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms. Am. J. Transplant. 2015, Published online February 3, 2015. http://dx.doi.org/10.1111/ajt.13174.
84. Anthony R.M., Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo. Curr. Opin. Organ Transplant. 2011, 16:7-14.
85. Goulabchand R., et al. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun. Rev. 2014, 13:742-750.
86. Jefferis R., et al. Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol. Lett. 1995, 44:111-117.
87. Lux A., Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 2011, 780:113-124.
88. Yang R., et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol. Dial. Transplant. 2010, 25:2479-2486.
89. Oefner C.M., et al. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 2012, 129:1647-1655.
90. Scherer H.U., et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010, 62:1620-1629.
91. Omtvedt L.A., et al. Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans. Arthritis Rheum. 2006, 54:3433-3440.
92. Wuhrer M., et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J. Proteome Res. 2009, 8:450-456.
93. Hess C., et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 2013, 123:3788-3796.
94. Lundström S.L., et al. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a Fab-peptide sequence. PLoS ONE 2014, 9:e113924.
95. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 2007, 7:803-815.
96. Valenzuela N.M., et al. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr. Opin. Organ Transplant. 2014, 19:33-40.
97. Li F., et al. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum. Immunol. 2011, 72:1150-1159.
98. Tible M., et al. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J. Heart Lung Transplant. 2013, 32:769-776.
99. Valenzuela N.M., et al. Blockade of P-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am. J. Transplant. 2013, 13:299-311.
100. Yamakuchi M., et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1301-1306.
101. Kuo H.H., et al. Platelets in early antibody-mediated rejection of renal transplants. J. Am. Soc. Nephrol. 2014, Published online August 21, 2014. http://dx.doi.org/10.1681/ASN. 2013121289.
102. López J.A. The platelet Fc receptor: a new role for an old actor. Blood 2013, 121:1674-1675.
103. Naemi F.M., et al. Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation 2013, 96:258-266.
104. Pober J.S., Tellides G. Participation of blood vessel cells in human adaptive immune responses. Trends Immunol. 2012, 33:49-57.
105. Cravedi P., et al. Complement regulation of T-cell alloimmunity. Semin. Nephrol. 2013, 33:565-574.
106. Taflin C., et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2891-2896.
107. Wang C., et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J. Clin. Invest. 2013, 123:1677-1693.
108. Jin Y.P., et al. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am. J. Transplant. 2014, 14:806-819.
109. Karsten C.M., Kohl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 2012, 217:1067-1079.
110. Shushakova N., et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J. Clin. Invest. 2002, 110:1823-1830.
111. Konrad S., et al. Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcγ receptor activation and immune complex-induced inflammation. J. Biol. Chem. 2008, 283:33296-33303.
112. i2 activation that controls C5aR and Fc receptor cooperation. J. Immunol. 2005, 174:3041-3050.
113. Kumar V., et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J. Clin. Invest. 2006, 116:512-520.
114. Cravedi P., et al. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am. J. Transplant. 2013, 13:2530-2539.